Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Omega-3 fatty acids and nonalcoholic fatty liver disease in adults and children

where do we stand?

Spooner, Melinda H.; Jump, Donald B.

Current Opinion in Clinical Nutrition & Metabolic Care: March 2019 - Volume 22 - Issue 2 - p 103–110
doi: 10.1097/MCO.0000000000000539
LIPID METABOLISM AND THERAPY: Edited by Philip C. Calder and Richard J. Deckelbaum
Buy
SDC

Purpose of review Nonalcoholic fatty liver disease (NAFLD) is the most common chronic fatty liver disease worldwide. The incidence of NAFLD parallels the prevalence of obesity. Moreover, NAFLD can progress to nonalcoholic steatohepatitis (NASH), cirrhosis and primary hepatocellular cancer (HCC). As such, NAFLD has become a major public health concern. We discuss recent clinical trials and meta-analyses evaluating the efficacy of C20-22 ω3 polyunsaturated fatty acids (PUFA) to attenuate preexisting NAFLD in adults and children.

Recent findings Humans with NAFLD and NASH; and preclinical mouse models of NASH, have a high abundance of hepatic saturated (SFA) and monounsaturated (MUFA) fat, but a low abundance of hepatic C20-22 ω3 PUFA. This change in hepatic fat type and abundance is associated with hepatic lipotoxicity, inflammation, oxidative stress and fibrosis. Recent meta-analyses and clinical trials evaluated the capacity of C20-22 ω3 PUFA dietary supplementation to improve health outcomes in adults and children with preexisting NAFLD. Diets supplemented with docosahexaenoic acid (DHA, 22 : 6,ω3) alone or with eicosapentaenoic acid (EPA, 20 : 5,ω3) are tolerated and effective at lowering liver fat in NAFLD patients. However, outcomes are mixed with respect to C20-22 ω3 PUFA attenuation of more severe NAFLD markers, such as hepatic injury, inflammation and fibrosis.

Summary These studies suggest that dietary supplementation with C20-22 ω3 PUFA should be considered as a viable and effective option to lower liver fat in obese adults and children with NAFLD.

Nutrition Program, School of Biological and Population Health Sciences, Linus Pauling Institute, Oregon State University, Corvallis, Oregon, USA

Correspondence to Donald B. Jump, PhD, School of Biological and Population Health Sciences, 107A Milam Hall, Oregon State University, Corvallis, OR 97331-5109, USA. Tel: +1 541 737 4007; fax: +1 541 737 6914; e-mail: Donald.Jump@oregonstate.edu

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.